Utility of novel viral and immune markers in predicting HBV treatment endpoints: A systematic review of treatment discontinuation studies.

JHEP Rep · 2023 · PMC10149368 · PMID 37138673

Europe PMC DOI

hedged sentence

0.0620

closest p · 1.2× alpha

0.0620

boldest claim

The sentences

near-significantp = 0.062so close (0.05 < p ≤ 0.1)

21 found a near-significant difference in 48-wk HBsAg seroclearance rates, 5.9% vs. 0% in patients with EOT HBcrAg <3 log U/ml and >3 log U/ml respectively ( p = 0.062).

also in 1,356 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.